# Gonadorelin Peptide

> Gonadorelin is synthetic GnRH, a hypothalamic decapeptide that stimulates pituitary LH and FSH release and controls reproductive-axis signaling.

Canonical: https://pepflow.app/peptides/gonadorelin/

The GnRH Signal

Gonadorelin is synthetic gonadotropin-releasing hormone, the hypothalamic decapeptide that signals the pituitary to release LH and FSH.

Fertility hormones

Tier B

Evidence Moderate

Safety Moderate Data

FDA status Not Listed

Last reviewed October 25, 2026 30 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is Gonadorelin?

Gonadorelin is synthetic gonadotropin-releasing hormone, the hypothalamic decapeptide that signals the pituitary to release LH and FSH.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>)

It has been used in diagnostic and reproductive-endocrine contexts, and pulsatile GnRH biology is foundational in fertility medicine.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>)

Current product availability and approval status are not the same as the biological identity. Compounded or clinic-supplied gonadorelin needs distinction from historical FDA product records and formal fertility protocols.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>)

## What Gonadorelin is investigated for

Gonadorelin evidence is grouped by practical use case and injectable and ophthalmic route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Pituitary function assessment Injectable 70% Moderate

Pituitary function assessment has the clearest gonadorelin evidence.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/17543719/>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>)

#### Human evidence

Human reproductive-axis literature supports GnRH/gonadorelin testing of pituitary gonadotropin response.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/17543719/>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>)

#### Animal / mechanistic evidence

The diagnostic rationale follows direct GnRH receptor stimulation of LH and FSH release.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/17543719/>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>)

### ### Pulsatile fertility-axis stimulation Injectable 68% Moderate

Fertility-axis stimulation depends on pulsatile, clinician-managed reproductive medicine contexts.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/39547644/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[18\]](<https://pubmed.ncbi.nlm.nih.gov/33238870/>)

#### Human evidence

Human reproductive medicine literature supports pulsatile GnRH approaches for selected hypothalamic fertility-axis disorders and ovulation-trigger strategy discussions.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/39547644/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[18\]](<https://pubmed.ncbi.nlm.nih.gov/33238870/>)

#### Animal / mechanistic evidence

The therapeutic rationale depends on physiologic pulsatile GnRH exposure rather than continuous stimulation.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/39547644/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[18\]](<https://pubmed.ncbi.nlm.nih.gov/33238870/>)

### ### Hypogonadotropic hypogonadism and testicular function Injectable 60% Emerging

Testicular-function support is condition-specific and is not general testosterone-boosting evidence.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/40099791/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[18\]](<https://pubmed.ncbi.nlm.nih.gov/33238870/>)

#### Human evidence

Clinical-management reviews and male-infant congenital hypogonadotropic hypogonadism data support selected testicular-function contexts.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/40099791/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[18\]](<https://pubmed.ncbi.nlm.nih.gov/33238870/>)

#### Animal / mechanistic evidence

The mechanism is restoration of downstream LH/FSH signaling through GnRH-axis activation.[\[8\]](<https://pubmed.ncbi.nlm.nih.gov/40099791/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[18\]](<https://pubmed.ncbi.nlm.nih.gov/33238870/>)

### ### Testosterone-sparing fertility support Injectable 16% Insufficient

TRT-alternative claims remain insufficient and separate from diagnostic and fertility-axis uses.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[18\]](<https://pubmed.ncbi.nlm.nih.gov/33238870/>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>)

#### Human evidence

Evidence for routine testosterone-sparing or TRT-alternative use is not established in the cited literature.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[18\]](<https://pubmed.ncbi.nlm.nih.gov/33238870/>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>)

#### Animal / mechanistic evidence

The rationale is extrapolated from GnRH-axis physiology and hypogonadotropic-hypogonadism management.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[18\]](<https://pubmed.ncbi.nlm.nih.gov/33238870/>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>)

## Evidence snapshot

### Overall confidence

Moderate

70%

Gonadorelin has moderate support as a GnRH tool in diagnostic and reproductive-endocrine protocols. Product status and timing-sensitive protocols limit broad usefulness.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

70%

### Human evidence

Moderate

Human endocrine testing and reproductive-axis protocols support GnRH activity, though product availability and protocol use vary.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)

34%

### Animal / preclinical

Limited

Mechanism is direct pituitary GnRH receptor stimulation.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)

70%

### Mechanism support

Moderate

Gonadorelin binds GnRH receptors on pituitary gonadotroph cells, triggering LH and FSH release. The mechanism sends the upstream signal for gonadal steroid and gamete-production pathways.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)

## Forms & administration

Gonadorelin is administered by injection in diagnostic and fertility care, including bolus and pulsatile-pump protocols. Eye-drop delivery remains experimental and animal-only. Its preparation and absorption differ from injectable products; it has no established human ophthalmic regimen.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[16\]](<https://pubmed.ncbi.nlm.nih.gov/1442098/>)

Injectable Ophthalmic

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Injectable protocols use 100-200 mcg per dose. Intranasal protocols use about 200 mcg per dose.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[17\]](<https://pubmed.ncbi.nlm.nih.gov/6108936/>)

### Frequency

Injections use 1-2 doses daily. Intranasal protocols use 6 doses daily.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[17\]](<https://pubmed.ncbi.nlm.nih.gov/6108936/>)

### Timing Considerations

Evening is the usual timing.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[17\]](<https://pubmed.ncbi.nlm.nih.gov/6108936/>)

### Cycle Length

Injectable cycles run 4-8 weeks. Intranasal courses run about 90 days.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[17\]](<https://pubmed.ncbi.nlm.nih.gov/6108936/>)

[Full Gonadorelin dosage guide](<https://pepflow.app/peptides/gonadorelin/dosage/>)

## What to expect

### Same day

Injectable gonadorelin can produce acute LH and FSH movement in diagnostic settings, with felt effects usually tied to downstream hormones.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>)

### Weeks 4-8

Injectable repeated or pulsatile protocols may show changes in LH/FSH patterns, testosterone or estradiol context, fertility goals, and symptoms.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>)

### After stopping

Reproductive-axis stimulation returns toward the underlying baseline after injectable gonadorelin exposure ends.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>)

## Safety profile

Gonadorelin safety depends on pulsatile versus continuous GnRH exposure, fertility context, sex-steroid response, and anti-doping status.[\[15\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

### Cautions

- Exposure pattern[\[15\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- Hormone-sensitive conditions[\[15\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- Fertility clinic context[\[15\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- Prohibited in sport[\[15\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

### What we don't know

Non-clinic repeated use, long-term axis effects, and product consistency remain poorly characterized outside supervised diagnostic or fertility settings.[\[15\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## Who Gonadorelin is not for

Route-specific avoid and medical-review notes:

- **Pregnancy unless specifically indicated and supervised**

  Pregnancy unless specifically indicated and supervised warrants medical review or avoidance for Gonadorelin.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)
- **Hormone-sensitive cancer without specialist review**

  Hormone-sensitive cancer without specialist review warrants medical review or avoidance for Gonadorelin.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)
- **Ovarian hyperstimulation risk without clinic oversight**

  Ovarian hyperstimulation risk without clinic oversight warrants medical review or avoidance for Gonadorelin.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **GnRH agonists / antagonists**

  Leuprolide, ganirelix, cetrorelix, or other GnRH-axis drugs can conflict with gonadorelin response patterns; this is a theoretical pathway caution.[\[15\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- **Gonadotropins / sex steroids**

  FSH, LH, hCG, testosterone, estrogen, or progestins can compound hormone-response and fertility-cycle effects; this is a theoretical pathway caution.[\[15\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- **Fertility medication stacks**

  Clomiphene, letrozole, or multi-drug fertility protocols can make cycle response and ovarian stimulation harder to attribute; this is a route-specific caution.[\[15\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## Regulatory status

### United States

In the U.S. as of 2026-06-21, gonadorelin has historical FDA approval context, but this page does not treat current research-market or compounded gonadorelin as FDA-approved for casual hormone-support use. FDA drug approval and compounding status remain separate buckets.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[20\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[21\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Not Listed · Gonadorelin is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[20\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[21\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) | Not Listed · Gonadorelin is not in the current reviewed 503A compounding bucket for the injectable route; compounding status is separate from FDA drug approval.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[20\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[21\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) |

### Injectable

FDA drug approval

Not Listed

Gonadorelin is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[20\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[21\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

503A compounding

Not Listed

Gonadorelin is not in the current reviewed 503A compounding bucket for the injectable route; compounding status is separate from FDA drug approval.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[20\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[21\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

### International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets.[\[23\]](<https://www.ema.europa.eu/en/medicines>) [\[24\]](<https://products.mhra.gov.uk/>) [\[25\]](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>) [\[26\]](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)

### Sports & competition

WADA S2 covers gonadorelin and GnRH analogues in hormone-axis manipulation; tested athletes should not treat gonadorelin as athlete-cleared without anti-doping review.[\[15\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) [\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[20\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[21\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

## How it works

Gonadorelin is synthetic GnRH, so it binds GnRH receptors on pituitary gonadotroph cells and triggers LH and FSH release. In practical terms, it sends the upstream signal that starts gonadal steroid and gamete-production pathways.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)

Injectable timing is the mechanism. Pulsatile GnRH can stimulate the reproductive axis, while continuous exposure can desensitize the receptor; that is why diagnostic bolus use, pulsatile pump therapy, fertility protocols, and casual hormone-support use are not equivalent. The route and rhythm are the therapeutic signal, not background details.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)

## Research gaps & open questions

What the current literature has not yet settled about Gonadorelin:

01

It is not always clear which gonadorelin products currently have FDA approval and which marketed versions are compounded or unapproved; each product needs current status verification.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)

02

Studies have not shown that compounded gonadorelin products match approved or previously approved products in strength, purity, release pattern, and clinical effect.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)

03

Safety and effectiveness are not well established when gonadorelin is used without endocrine or fertility supervision or for wellness and performance goals.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)

## Common questions

### Is gonadorelin GnRH?

Yes. Gonadorelin is synthetic GnRH, the upstream pituitary signal that can trigger LH and FSH release.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>)

### Is gonadorelin the same as hCG?

No. Gonadorelin signals the pituitary upstream, while hCG acts downstream at LH/CG receptors in the gonads.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>)

### Is gonadorelin FDA-approved now?

No. Current casual hormone-support or compounded/research-market gonadorelin use is not the same as historical FDA approval or supervised diagnostic/fertility contexts.[\[13\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>) [\[14\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[20\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)

## Myths & misconceptions

### Myth

More gonadorelin always means more hormones.

### Reality

Continuous GnRH signaling can desensitize receptors; pulse pattern matters.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)

### Myth

Gonadorelin is testosterone replacement.

### Reality

It stimulates the reproductive axis and is not exogenous testosterone.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)

## History & discovery

Gonadorelin followed the discovery of GnRH/LHRH as the hypothalamic signal controlling pituitary LH and FSH release. Its history is built around timing and endocrine axis testing. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)

Gonadorelin became useful because a bolus could probe hypothalamic-pituitary-gonadal axis responsiveness. That diagnostic history differs from casual hormone-support use.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)

Fertility and hypogonadotropic-hypogonadism literature showed that pulsatile delivery can stimulate the axis while continuous exposure can desensitize it. Timing became part of the mechanism.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/29544634/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/30698671/>) [\[3\]](<https://pubmed.ncbi.nlm.nih.gov/30674181/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)

## Published research 30 citations

- [\[1\] **GnRH in the Human Female Reproductive Axis.** Vitam Horm, 2018. review.](<https://pubmed.ncbi.nlm.nih.gov/29544634/>)
- [\[2\] **Clinical Management of Congenital Hypogonadotropic Hypogonadism.** Endocr Rev, 2019 Apr 1. review.](<https://pubmed.ncbi.nlm.nih.gov/30698671/>)
- [\[3\] **Advances in ovulation trigger strategies.** Panminerva Med, 2019 Mar. review.](<https://pubmed.ncbi.nlm.nih.gov/30674181/>)
- [\[4\] **A Current Perspective on Delayed Puberty and Its Management.** J Clin Res Pediatr Endocrinol, 2024 Dec 4. review.](<https://pubmed.ncbi.nlm.nih.gov/38683021/>)
- [\[5\] **EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome.** Ann Rheum Dis, 2017 Mar. review.](<https://pubmed.ncbi.nlm.nih.gov/27457513/>)
- [\[6\] **Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women.** Medicina (Kaunas), 2022 Sep 11. review.](<https://pubmed.ncbi.nlm.nih.gov/36143933/>)
- [\[7\] **Triggering oocyte maturation in in vitro fertilization treatment in healthy responders: a systematic review and network meta-analysis.** Fertil Steril, 2025 May. review.](<https://pubmed.ncbi.nlm.nih.gov/39547644/>)
- [\[8\] **Efficacy and safety of pulsatile GnRH pump therapy in male infants with congenital hypogonadotropic hypogonadism.** Endocr Connect, 2025 May 1. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/40099791/>)
- [\[9\] **Ovarian reserve.** Ann N Y Acad Sci, 2008 Apr. review.](<https://pubmed.ncbi.nlm.nih.gov/18443326/>)
- [\[10\] **Hypogonadotropic hypogonadism.** Endocrinol Metab Clin North Am, 2007 Jun. review.](<https://pubmed.ncbi.nlm.nih.gov/17543719/>)
- [\[11\] **Cycle regimens for endometrial preparation prior to frozen embryo transfer.** Cochrane Database Syst Rev, 2025 Jun 3. review.](<https://pubmed.ncbi.nlm.nih.gov/40458990/>)
- [\[12\] **The role of pharmacotherapy in the treatment of endometriosis: an update.** Expert Opin Pharmacother, 2025 Dec. review.](<https://pubmed.ncbi.nlm.nih.gov/41328046/>)
- [\[13\] **Drugs@FDA/openFDA query for Gonadorelin** U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22Gonadorelin%22&limit=1>)
- [\[14\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[15\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[16\] **Effects of permeation enhancers BL-9 and Brij-78 on absorption of four peptide eyedrops in rabbits.** Zhongguo yao li xue bao = Acta pharmacologica Sinica, 1992 May. animal.](<https://pubmed.ncbi.nlm.nih.gov/1442098/>)
- [\[17\] **Treatment of delayed puberty by intranasal application of gonadotropin-releasing hormone (GnRH).** Int J Fertil, 1980. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/6108936/>)
- [\[18\] **GnRH in the Treatment of Hypogonadotropic Hypogonadism.** Curr Pharm Des, 2021. review.](<https://pubmed.ncbi.nlm.nih.gov/33238870/>)
- [\[19\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[20\] **Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)
- [\[21\] **Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act** U.S. Food and Drug Administration, 2025-01-07. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)
- [\[22\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[23\] **European Medicines Agency medicines search** European Medicines Agency. official guidance.](<https://www.ema.europa.eu/en/medicines>)
- [\[24\] **MHRA Products search** Medicines and Healthcare products Regulatory Agency. official guidance.](<https://products.mhra.gov.uk/>)
- [\[25\] **Drug Product Database: Access the database** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>)
- [\[26\] **Searching the Australian Register of Therapeutic Goods** Therapeutic Goods Administration. official guidance.](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)
- [\[27\] **Cosmetic Products Regulation** European Commission. official guidance.](<https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en>)
- [\[28\] **Making cosmetic products available to consumers in Great Britain** UK Office for Product Safety and Standards. official guidance.](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>)
- [\[29\] **Cosmetics regulatory information** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>)
- [\[30\] **Cosmetics and soap** Australian Industrial Chemicals Introduction Scheme. official guidance.](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Endocrine/reproductive hormone

**Tier**

B

**Evidence**

70% Moderate

**Safety**

Moderate Data

**FDA status**

Not Listed

**Injectable 503A**

Not Listed

**Citations**

[30 citations](<https://pepflow.app/peptides/gonadorelin/#published-research>)

**Updated**

October 25, 2026

### Potential benefits

- Pituitary function assessment
- Pulsatile fertility-axis stimulation
- Hypogonadotropic hypogonadism and testicular function
- Testosterone-sparing fertility support

### Also known as

- Gonadotropin-releasing hormone
- GnRH
- LHRH
- Luteinizing hormone-releasing hormone

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [Gonadorelin dosage guide](<https://pepflow.app/peptides/gonadorelin/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
